English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

From February 2014 to 2016, we recruited 80 patients with malignant glioma in the Renmin Hospital of Wuhan University. To study the effect of radiotherapy and chemotherapy on the levels of serum S100 calcium-binding protein B (S100B), interleukin 6 (IL-6), and interleukin 17 (IL-17), all patients were divided into two groups randomly and evenly. In one group, all 40 patients received the three-dimensional conformal radiotherapy (3D-CRT). In another group, all patients received combinatorial treatment of 3D-CRT and temozolomide (TMZ). The therapeutic effect, immune function index before and after the treatment, change of serum S100B, IL-6, and IL-17 levels as well as adverse reactions were analyzed and compared between those two groups. We found that the effective rate of the combination group was 82.5%, which is significantly higher than 52.5% in the control group. After treatment, the number of CD3+, CD4+, and NK cells in the combination group was higher. But, CD8+ cells were lower compared with those before treatment. The levels of serum S100B, IL-6, and IL-17 in both groups were lower than those before treatment. In conclusion, radiotherapy combined with chemotherapy is more effective than radiotherapy alone in the treatment of malignant cerebral gliomas and is worthy of clinical spreading.

Effect of radiotherapy and chemotherapy on levels of serum S100B, IL-6, and IL-17 in patients with malignant glioma